9.4 Health Promotion, Disease Prevention, and Public Health
Key Takeaways
- Disease prevention spans five distinct levels: primordial (population policy), primary (preventing disease onset), secondary (early asymptomatic screening), tertiary (managing chronic complications), and quaternary (preventing overdiagnosis and overtreatment).
- Naloxone is a pure competitive opioid antagonist with a short elimination half-life (30-90 minutes), requiring mandatory emergency medical transport (911) to prevent fatal renarcotization after naloxone wears off.
- Missing 3 or more consecutive daily doses of opioid agonist therapy (methadone or buprenorphine) causes significant loss of opioid tolerance, requiring prescriber consultation and dose reduction before redispensing.
- Combination Nicotine Replacement Therapy (NRT patch plus PRN short-acting formulation) and varenicline represent first-line smoking cessation pharmacotherapy; bupropion SR is strictly contraindicated in patients with seizure or active eating disorders.
- Maintaining vaccine cold-chain integrity between 2°C and 8°C is essential; temperature excursions require immediate isolation of vaccines in a functioning unit labeled 'DO NOT USE' pending public health review.
Last updated: August 2026
9.4 Health Promotion, Disease Prevention, and Public Health
Exam Focus: Public health promotion, immunization advocacy, harm reduction strategies, and disease prevention levels are core competencies tested on the PEBC Evaluating Examination. Pharmacists must differentiate the five levels of prevention, manage vaccine storage and cold-chain excursions, execute opioid overdose reversal protocols with take-home naloxone, adhere to Opioid Agonist Therapy (OAT) safety rules, select evidence-based smoking cessation regimens, and practice antimicrobial stewardship.
The Spectrum of Disease Prevention
Public health strategies and clinical pharmacy interventions are categorized across five distinct levels of prevention.
+-------------------------------------------------------------------------+
| THE SPECTRUM OF DISEASE PREVENTION |
+-------------------------------------------------------------------------+
| 1. PRIMORDIAL PREVENTION |
| Target: Underlying social, economic & environmental conditions |
| Action: National tobacco excise taxes; trans fat food bans |
| | |
| v |
| 2. PRIMARY PREVENTION |
| Target: Specific disease risk factors before pathology occurs |
| Action: Routine vaccinations; HIV PrEP; folic acid in pregnancy |
| | |
| v |
| 3. SECONDARY PREVENTION |
| Target: Early asymptomatic disease detection |
| Action: Pharmacy BP screening clinics; point-of-care HbA1c testing |
| | |
| v |
| 4. TERTIARY PREVENTION |
| Target: Established symptomatic chronic disease |
| Action: Post-MI dual antiplatelet therapy; stroke rehabilitation |
| | |
| v |
| 5. QUATERNARY PREVENTION |
| Target: Patients at risk of overmedicalization & adverse events |
| Action: Deprescribing inappropriate medications (Beers / STOPP) |
+-------------------------------------------------------------------------+
| Level of Prevention | Primary Target | Core Mechanism | Pharmacy Clinical Example |
|---|---|---|---|
| Primordial | General Population | Modifying broad environmental, economic, and social determinants | Advocating for clean air bylaws, trans fat bans, or municipal tobacco sales restrictions |
| Primary | At-Risk Individuals | Preventing the initial biological onset of disease | Administering HPV vaccines to prevent cervical dysplasia; prescribing HIV PrEP |
| Secondary | Asymptomatic Individuals | Detecting subclinical disease early to halt progression | Performing capillary blood glucose or blood pressure screenings; distributing colorectal FIT kits |
| Tertiary | Diagnosed Patients | Managing symptomatic disease to prevent death and disability | Optimizing ACE inhibitor and beta-blocker therapy in heart failure; diabetic foot ulcer care |
| Quaternary | Over-Treated Patients | Protecting patients from unnecessary diagnostic/drug interventions | Deprescribing long-term proton pump inhibitors or sedatives in elderly patients |
Pharmacist-Led Immunization and Cold-Chain Management
Pharmacists across all Canadian provinces and territories are authorized to administer vaccines via intramuscular and subcutaneous injection, playing a vital role in national immunization coverage.
National Advisory Committee on Immunization (NACI) Key Guidelines
- Influenza: Annual seasonal vaccination for all individuals $\ge 6$ months of age; high-dose or adjuvanted trivalent/quadrivalent formulations are prioritized for adults aged $\ge 65$ years.
- Pneumococcal Disease: NACI guidelines recommend Pneumococcal Conjugate Vaccines (PCV20 alone or PCV15 followed by Pneumovax 23) for adults aged $\ge 65$ years and adults aged $18\text{ to }64$ years with immunocompromising conditions or chronic medical risks (e.g., diabetes, chronic lung/heart/kidney/liver disease).
- Herpes Zoster (Shingles): Recombinant zoster vaccine (RZV, Shingrix; 2 doses administered intramuscularly at 0 and 2-6 months) is strongly recommended for immunocompetent adults $\ge 50$ years and immunocompromised adults $\ge 18$ years.
- Overcoming Vaccine Hesitancy: Use Motivational Interviewing (MI) and the presumptive recommendation approach (e.g., "You are due for your annual flu vaccine today, so we will get that done for you alongside your refill") which achieves significantly higher vaccine uptake than tentative or passive questions.
Cold-Chain Integrity and Excursion Protocols
Vaccine potency is permanently lost when products are exposed to temperatures outside their specified ranges; once lost, potency cannot be restored by re-cooling or re-freezing.
+-------------------------------------------------------------------------+
| VACCINE STORAGE & EXCURSION PROTOCOL |
+-------------------------------------------------------------------------+
| REFRIGERATED STORAGE: Strictly maintained at 2°C to 8°C (36°F to 46°F) |
| FROZEN STORAGE: Strictly maintained at -50°C to -15°C (-58°F to 5°F) |
| |
| COLD-CHAIN EXCURSION WORKFLOW: |
| 1. Immediately isolate affected vaccines in a properly functioning |
| refrigerator labeled clearly: "DO NOT USE - UNDER INVESTIGATION" |
| 2. DO NOT DISCARD VACCINES until instructed |
| 3. Record minimum/maximum temperatures and duration of excursion |
| 4. Contact local Public Health unit & manufacturers for stability data |
+-------------------------------------------------------------------------+
Harm Reduction and Substance Use Disorders
Harm reduction is an evidence-based, compassionate public health approach aimed at reducing the negative health, social, and economic consequences associated with substance use, without requiring abstinence as a mandatory condition of care.
Take-Home Naloxone (THN) Kits and Overdose Management
+-------------------------------------------------------------------------+
| OPIOID OVERDOSE RECOGNITION & RESPONSE |
+-------------------------------------------------------------------------+
| TRIAD OF OPIOID OVERDOSE: |
| 1. Central nervous system depression (unconsciousness / coma) |
| 2. Severe respiratory depression (slow, shallow breathing, or apnea) |
| 3. Pinpoint pupils (miosis; may be absent in severe hypoxic anoxia) |
| |
| "SAVE ME" RESUSCITATION PROTOCOL: |
| - S: Stimulate (verbal check, sternal rub) |
| - A: Airway (check for obstruction) |
| - V: Ventilate (provide rescue breaths, 1 breath every 5 seconds) |
| - E: Evaluate (assess responsiveness) |
| - M: Medicate (administer Naloxone IM 0.4 mg or Intranasal 4 mg) |
| - E: Evaluate & Re-dose (repeat naloxone every 2-3 minutes if no response)|
+-------------------------------------------------------------------------+
- Pharmacology: Naloxone is a pure competitive antagonist at $\mu$, $\kappa$, and $\delta$ opioid receptors with no intrinsic agonist activity. It rapidly displaces opioids, reversing respiratory and CNS depression within 2 to 5 minutes.
- The Critical Kinetic Problem (Renarcotization): The elimination half-life of naloxone is short ($t_{1/2} \approx 30\text{ to }90\text{ minutes}$). Potent synthetic opioids (fentanyl, carfentanil, nitazenes) and long-acting opioids (methadone, sustained-release morphine) have much longer half-lives (up to 24-36 hours). Once naloxone is cleared, residual opioids will re-bind to receptors, causing recurrent respiratory depression (renarcotization). Therefore, calling 911 (emergency medical services) is mandatory in all overdose resuscitations.
Opioid Agonist Therapy (OAT) Safety Rules
- Buprenorphine/Naloxone (Suboxone): First-line therapy for opioid use disorder under Canadian guidelines. Partial $\mu$-agonist with high affinity and ceiling effect for respiratory depression. The sublingual naloxone component has negligible oral bioavailability ($<10%$) but precipitates severe withdrawal if crushed and injected intravenously.
- Methadone: Full $\mu$-opioid agonist. High bioavailability, long half-life ($t_{1/2} \approx 24\text{ to }36\text{ hours}$), narrow therapeutic index, and risk of fatal overdose during initiation. Prolongs QTc interval; extensive CYP3A4 and CYP2D6 interactions.
- Missed Dose Safety Protocol:
- Missing 3 or more consecutive daily doses ($\ge 3$ days) results in a substantial loss of opioid tolerance.
- Mandatory Rule: Pharmacists must not dispense the regular full maintenance dose if $\ge 3$ consecutive doses are missed. The pharmacist must contact the prescriber to implement a mandatory dose reduction or re-induction protocol to prevent fatal overdose.
+-------------------------------------------------------------------------+
| OAT MISSED DOSE PHARMACY MANAGEMENT |
+-------------------------------------------------------------------------+
| - 1-2 Consecutive Missed Doses: Dispense regular maintenance dose |
| - 3-4 Consecutive Missed Doses: DO NOT DISPENSE FULL DOSE; consult |
| prescriber for dose reduction (typically restart at 50% dose) |
| - ≥ 5 Consecutive Missed Doses: Cancel prescription; patient requires |
| formal medical reassessment and full re-induction from starting dose |
+-------------------------------------------------------------------------+
Tobacco and Smoking Cessation Pharmacotherapy
Tobacco use remains the leading cause of preventable premature death in Canada. Pharmacists utilize the 5 A's Model (Ask, Advise, Assess, Assist, Arrange) and evidence-based pharmacotherapy.
+-------------------------------------------------------------------------+
| FIRST-LINE SMOKING CESSATION PHARMACOTHERAPY |
+-------------------------------------------------------------------------+
| 1. COMBINATION NICOTINE REPLACEMENT THERAPY (NRT): |
| Long-acting patch (basal control) + Short-acting form (gum, lozenge,|
| inhaler, oral spray) PRN for acute breakthrough cravings |
| |
| 2. VARENICLINE (Champix): |
| Partial α4β2 nicotinic receptor agonist; blocks nicotine reward |
| Dosing: 0.5 mg daily x 3 days, 0.5 mg BID x 4 days, then 1 mg BID |
| Side effects: Nausea (take with food & water), insomnia, vivid dreams|
| |
| 3. BUPROPION SR (Zyban): |
| Inhibits dopamine and norepinephrine reuptake |
| Dosing: 150 mg daily x 3 days, then 150 mg BID (taken 8 hrs apart) |
| CONTRAINDICATIONS: Seizure history, active anorexia/bulimia, MAOIs |
+-------------------------------------------------------------------------+
| Pharmacotherapy | Mechanism of Action | Clinical Dosing Strategy | Key Contraindications & Warnings |
|---|---|---|---|
| Combination NRT | Replaces tobacco nicotine; stimulates nicotinic cholinergic receptors | Patch (Step 1: 21 mg/24h if $\ge 10$ cig/day x 4-6 wks, then taper) PLUS gum/lozenge/spray PRN | Recent acute myocardial infarction ($<2$ weeks), unstable angina, severe arrhythmias |
| Varenicline | Selective partial agonist at $\alpha_4\beta_2$ nicotinic receptors | Start 1-2 weeks before quit date: 0.5 mg daily x 3d $\rightarrow$ 0.5 mg BID x 4d $\rightarrow$ 1 mg BID x 12 wks | Severe renal impairment (requires dose reduction); neuropsychiatric symptom monitoring |
| Bupropion SR | Norepinephrine and dopamine reuptake inhibitor (NDRI) | Start 1-2 weeks before quit date: 150 mg daily x 3d $\rightarrow$ 150 mg BID x 7-12 wks | Strictly contraindicated in seizure disorders, eating disorders (anorexia/bulimia), and MAOI use |
Antimicrobial Stewardship and Public Health Surveillance
Antimicrobial resistance (AMR) is a global public health threat. Canadian pharmacists support antimicrobial stewardship under Choosing Wisely Canada:
- Upper Respiratory Tract Infections: Withhold antibiotics for self-limiting viral conditions (common cold, viral pharyngitis, acute bronchitis, uncomplicated viral rhinosinusitis).
- Asymptomatic Bacteriuria (ASB): Do not screen or treat asymptomatic bacteriuria with antibiotics in older adults, catheterized patients, or non-pregnant individuals.
- Delayed / "Back-Pocket" Prescriptions: Educate patients to fill antibiotic prescriptions only if symptoms worsen after 48-72 hours of symptomatic supportive care.
- Mandatory Public Health Reporting: Pharmacists must immediately notify local public health departments regarding statutory reportable communicable diseases (e.g., measles, tuberculosis, invasive meningococcal disease, syphilis).
Test Your Knowledge
A community pharmacy hosts a weekend health promotion event where pharmacy students offer free blood pressure checks, capillary fingerstick blood glucose screenings, and distribution of Fecal Immunochemical Test (FIT) kits for asymptomatic older adults. Which level of disease prevention does this screening clinic represent?
A
B
C
D
Test Your Knowledge
A bystander successfully administers a single dose of intramuscular naloxone to an unresponsive individual experiencing an acute fentanyl overdose. Within three minutes, the individual regains consciousness and begins breathing normally. Why is it critically necessary to immediately transport this patient to an emergency department via 911?
A
B
C
D
Test Your Knowledge
A patient enrolled in a daily witnessed methadone maintenance program for severe opioid use disorder has missed four (4) consecutive daily doses due to incarceration and travel delays. How must the community pharmacist manage this prescription when the patient arrives at the dispensary?
A
B
C
D
Test Your Knowledge
A 42-year-old patient with a 20 pack-year smoking history wishes to initiate pharmacotherapy for smoking cessation. The patient's medical history is significant for a history of generalized tonic-clonic seizures and bulimia nervosa. Which of the following smoking cessation pharmacotherapies is strictly contraindicated in this patient?
A
B
C
D